Share
30,340 Posts.
lightbulb Created with Sketch. 1837
clock Created with Sketch.
09/01/21
13:36
Share
Originally posted by bedger:
↑
Not really anything wrong with shorting and putting informative insights on here as to why you are, anymore than long posters putting on why they are long. Lets keep the squabbling down people. Nothing wrong with a bit of objective debate and correcting misinformation. So much crap around. The ARDS trial end to recruitment was reported as a failed Novartis partnership trial in some parts of the finance media! Last time I checked Novartis had nothing to do with it and it was funded by the NIH and operated by Mount Sinai under the US national clinical trial testing network that they are a lead partner in under the NIH ultimately. Novartis will be looking at the full data with Mesoblast when 60 day end-points are complete (per the official release). I feel very confident Novartis will be keen to explore other avenues with MSB in non-COVID (and possibly COVID) ARDS, including an all-ARDS phase 3 trial per the original agreement. People need to go and re-read the original collaboration agreement: Key transaction terms: • Novartis will make a US$50 million upfront payment including US$25 million in equity. • From the initiation of a Phase 3 trial in all-cause ARDS , Novartis will fully fund global clinical development for all-cause ARDS and potentially other respiratory indications. • Mesoblast may receive a total of US$505 million pending achievement of precommercialization milestones for ARDS indications. • Mesoblast may receive additional payments post-commercialization of up to US$750 million based on achieving certain sales milestones and tiered double-digit royalties on product sales. • Mesoblast will retain full rights and economics for remestemcel-L for graft versus host disease (GVHD), and Novartis has an option to, if exercised, become the commercial distributor outside of Japan. • For most non-respiratory indications, the parties may co-fund development and commercialization on a 50:50 profit-share basis. • Mesoblast will be responsible for clinical and commercial manufacturing and Novartis will purchase commercial product under agreed pricing terms. Novartis will reimburse Mesoblast up to US$50 million on the achievement of certain milestones related to the successful implementation of its next-generation manufacturing processes using its proprietary media and three-dimensional bioreactors aimed at delivering substantial manufacturing efficiencies. Novartis will be responsible for any capital expenditure required to meet increased capacity requirements for manufacture of remestemcel-L. The above are indisputable facts. I am of the opinion that Novartis will be very keen to explore the COVID-19 ARDS results with a view to both COIVD-19 ARDS and non-COVID-19 ARDS, per the partnership agreement above and likely commence a well designed all cause ARDS trial per their original intentions. Its a partnership people, not a binary take over subject to the ARDS results...
Expand
Not really anything wrong with shorting and putting informative insights on here as to why you are, anymore than long posters putting on why they are long. Not the same thing. It's far easier to raise fear and doubt, than it is to provide an incremental understanding of the stock. The latter requires building and rebuilding over and over and OVER. To even begin to even the scales up. It's a shorter's feast in here and always has been. Those LTers who have tired of the antics are off in the seclusion of a different platform and they are taking advantage of the low SP for cheap entry points. THIS is the reality. It's a really tough situation and not at all possible to even it up with corresponding replies. DYOR people and beware of exaggerations and dramas.